title: [Study on effects of kurarinol combined with glycyrrhizic acid on cellular immunity of patients with chronic hepatitis B].
abstract: OBJECTIVE
  To explore effects of kurarinol combined with Diammonium Glycyrrhizinate on specific cellular immunity of patients with chronic hepatitis B (CHB).
  
  
  METHODS
  Sixty-three CHB patients were randomly divided into two groups, 32 cases in group of kurarinol combined with Diammonium Glycyrrhizinate group (combined therapy group) were treated with 600 mg kurarinol glucose injection intravenously, once a day for one month, then 200 mg kurarinol capsule was used orally, three times a day for two months. 150 mg Diammonium Glycyrrhizinate for Injection was added to 250 ml 10% glucose injection for intravenous drip, once a day for one month, then 150 mg Diammonium Glycyrrhizinate capsule was used orally, three times a day for two months; 31 case in kurarinol group (single drug group) only used kurarinol, methods and dosage were the same as those of treatment group. HBV specific CTL, T cell subgroups, change of Th1 and Th2 level, HBV-DNA and HBeAg negative rate of the two groups were compared.
  
  
  RESULTS
  Three months after treatment, HBV specific CTL, CD4 + and Th1 of combined therapy group were higher than those before treatment, and higher than those of single drug group after treatment (P < 0.01).
  
  
  CONCLUSIONS
  HBV-DNA and HBeAg negative rate between the two groups had no statistic significance (P > 0.05).
  
  
  CONCLUSIONS
  Kurarinol combined with Diammonium Glycyrrhizinate can further increase HBV specific CTL, CD4+ and Th1 level of CHB patients.
authors.affiliation: Wuxi Hospital for Infectious Diseases, 214005 China. gxb188681@sina.com
authors.forename: Xi-Bing
authors.initials: XB
authors.lastname: Gu
authors.forename: Xiao-Juan
authors.initials: XJ
authors.lastname: Yang
authors.forename: Xiang-Hu
authors.initials: XH
authors.lastname: Jiang
authors.forename: Zhong
authors.initials: Z
authors.lastname: Hua
authors.forename: Zhong-Hua
authors.initials: ZH
authors.lastname: Lu
authors.forename: Bo
authors.initials: B
authors.lastname: Zhang
authors.forename: Yin-Fang
authors.initials: YF
authors.lastname: Zhu
authors.forename: Hang-Yuan
authors.initials: HY
authors.lastname: Wu
authors.forename: Yi-Ming
authors.initials: YM
authors.lastname: Jiang
authors.forename: Hao-Kun
authors.initials: HK
authors.lastname: Chen
authors.forename: Hao
authors.initials: H
authors.lastname: Pei
authors.forename: Yu-Lin
authors.initials: YL
authors.lastname: Zhou
mesh_terms: D000328:Adult; D004279:DNA, Viral / Q000032:analysis; D004359:Drug Therapy, Combination; D005260:Female; D005419:Flavonoids / Q000008:administration & dosage*; D019695:Glycyrrhizic Acid / Q000008:administration & dosage*; D006513:Hepatitis B e Antigens / Q000032:analysis; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D008297:Male; D008875:Middle Aged
chemical_list: D004279:DNA, Viral; D005419:Flavonoids; D006513:Hepatitis B e Antigens; C526229:kurarinol; D019695:Glycyrrhizic Acid